Is the Digital Health Market growing now?
In our digital health market deck, you will find everything you need to understand the market
SUMMARY
Yes. The Digital Health Market is growing now, with rising revenue, healthcare usage, AI adoption, acquisitions and U.S. venture funding. The catch is that much of this growth is concentrating around a relatively small group of strong companies.
U.S. venture funding has recovered without a similar rebound in deal count. Startups raised $7.4 billion in the first half of 2026, up 15.6% year over year, while the number of deals was almost perfectly flat.
That concentration is becoming extreme. Just over 8% of U.S. funding rounds captured 45% of all capital, while global digital-health deal activity recently fell to its lowest quarterly level in more than a decade.
Commercial performance looks healthier than startup activity. Six major digital-health companies generated roughly $2.20 billion of quarterly revenue, about 20% more than a year earlier, and the five excluding Teladoc grew about 32%.
Telehealth has survived the post-pandemic reset. Commercial telehealth claims recently increased again and remain roughly 26 times their 2019 share, even though first-generation telehealth companies such as Teladoc and BetterHelp are struggling.
Digital mental health and obesity care are becoming more integrated with insurance, prescribing and recurring clinical care. That favors companies built around psychiatry, chronic care and medication-supported programs rather than generic virtual consultations.
AI is creating one of the biggest shifts inside the market. Physician professional AI usage has risen from 38% in 2023 to 81%, while consumer use of AI chatbots for health information doubled in one year.
AI also makes weak digital-health products easier to replace. Distribution, proprietary clinical data, contracted populations, reimbursement access and deep workflow integration are becoming more defensible than simply putting a healthcare interface around a general model.
The economics of leading companies are improving too. Omada, Tempus, Doximity and Hinge Health have all shown that meaningful digital-health growth can coexist with positive earnings, EBITDA or cash generation, although profitability is still far from universal.
M&A reinforces the same pattern. Larger healthcare and software platforms are buying digital-health businesses that already own useful workflows, patient relationships or datasets, while IPO investors are reopening the market mainly for companies with scale and credible economics.
The result is a market that feels strong and harsh at the same time. Digital healthcare itself is expanding, but the number of startups able to capture that growth is narrowing. This is increasingly a consolidation cycle rather than a repeat of the broad 2021 funding boom.
This market map, featured in our digital health market deck, highlights top companies and startups in the digital health market
What counts as the digital health market today?
The digital health market today is much bigger than telehealth, and that broader definition changes the answer to whether the market is growing.
Digital health now covers virtual care, chronic-care platforms, clinical AI, healthcare workflow software, remote monitoring, wearables, digital mental health, consumer health platforms and parts of precision medicine. Some databases stretch even further into AI drug discovery.
That last boundary can distort the numbers. CB Insights, for example, includes businesses such as Isomorphic Labs, whose $2.1 billion AI drug-design round was large enough to move the entire global digital-health funding total in one quarter. A giant drug-discovery financing tells us something about health technology investment, but very little about whether employers are buying more virtual care or patients are using more telehealth.
So we need to look beyond one market-size number. For this analysis, the useful test is whether more healthcare activity and money are moving through digital products: revenue, patients, clinicians, contracts, funding and acquisitions. That gives us a much cleaner picture of what is actually growing.
If you want more recent data on this point, please see our latest digital health market report.
Is U.S. digital health funding really growing again?
Yes, U.S. digital health funding is currently growing again, with almost exactly the same number of deals as a year ago.
Rock Health's latest half-year count puts U.S. digital-health venture funding at $7.4 billion across 244 deals, up from $6.4 billion across 245 deals during the same period a year earlier. Investors put roughly $1 billion more into the market without financing more companies.
This is also part of a longer recovery. U.S. digital-health startups raised $14.2 billion in 2025, according to Rock Health, 35% more than in 2024 and the highest annual amount since 2022.
We are still far from the extraordinary 2021 funding environment, when U.S. digital health attracted $29.3 billion over the full year. Today's numbers can look like another boom when viewed only against the post-crash years.
The current recovery is healthier and much narrower. Funding has moved materially above the 2023-2024 trough, but investors are nowhere near the indiscriminate spending of 2021.
| U.S. digital health funding | Capital raised | Deals |
|---|---|---|
| H1 2025 | $6.4B | 245 |
| H1 2026 | $7.4B | 244 |
| Change | +15.6% | Essentially flat |
As this chart shows, and as featured in our digital health market deck, search interest in longevity apps and related topics has been increasing
Are investors funding more digital health startups, or just writing bigger checks?
Investors are mainly writing bigger digital health checks these days, while the number of startups getting funded has barely moved.
The contrast is unusually clear. Rock Health counted 244 U.S. deals in the first half of 2026 versus 245 a year earlier, yet total capital rose 15.6%. The median deal reached $14 million, its highest level since 2022.
The top of the market explains much of the gap. Nineteen companies completed 20 rounds worth at least $100 million, and those rounds absorbed 45% of all U.S. digital-health funding. Just over 8% of deals therefore captured almost half the money. Mega-rounds represented only 22% of funding in 2024.
The companies receiving those large checks also show where investor conviction sits. WHOOP raised $575 million. OpenEvidence raised $250 million. Talkiatry raised $210 million. eMed raised $200 million. Grow Therapy and Aidoc each raised $150 million.
The rebound is selective. Investors are paying heavily for companies that already have distribution, clinical data, healthcare expertise or visible scale. Simply being a digital-health startup is no longer enough to benefit.
If you want more recent data on this point, please see our latest digital health market report.
Is global digital health funding growing too?
Global digital health is currently much weaker by deal count than the U.S. funding headline suggests.
CB Insights counted only 228 global digital-health equity deals in the latest quarter, down 36% from the previous quarter and the lowest quarterly total in more than a decade. Funding fell 24% to $5.7 billion.
Even $5.7 billion makes the market look broader than it was. Ten mega-rounds captured 60% of all capital. Isomorphic Labs alone raised $2.1 billion, equal to roughly 37% of the entire quarter's global funding.
Median deal size still rose sharply. CB Insights puts the year-to-date median at $7.7 million, 54% higher than the 2025 median. Fewer companies are raising money, but successful rounds are getting larger.
The U.S. and global datasets use different definitions, so their absolute totals should not be mixed. Their direction is remarkably similar, though: capital is becoming concentrated around a smaller group of companies.
That makes it hard to describe the startup ecosystem itself as booming. Digital health can grow commercially while startup dealmaking contracts.
This chart, featured in our digital health market deck, shows annual VC investment in digital health startups
Are digital health companies actually growing revenue now?
Yes, several major digital health companies are growing revenue quickly right now, and the combined numbers are strong even after including a shrinking Teladoc.
We combined the latest comparable quarterly revenue from Hims & Hers, Hinge Health, Omada Health, Tempus AI, Doximity and Teladoc Health. Together, the six companies generated about $2.20 billion versus $1.84 billion a year earlier, growth of roughly 20%.
Teladoc drags that average down. Excluding Teladoc, the other five increased combined revenue by about 32%.
The individual numbers show that this growth is coming from very different parts of digital health. Hims & Hers grew 38% to $753 million. Hinge Health grew 53% to $213 million. Omada grew 43% to $88 million. Tempus grew 22% to $383 million. Doximity grew a more modest 7% to $157 million.
Meanwhile, Teladoc revenue fell 4% to $607 million, with BetterHelp down 12%. That keeps the picture realistic. Newer or better-positioned digital-health models are growing while some first-generation leaders struggle.
| Company | Latest quarterly revenue | YoY growth |
|---|---|---|
| Hims & Hers | $753M | +38% |
| Teladoc Health | $607M | -4% |
| Tempus AI | $383M | +22% |
| Hinge Health | $213M | +53% |
| Doximity | $157M | +7% |
| Omada Health | $88M | +43% |
Are employers and health plans buying digital health at real scale now?
Yes, the stronger digital health platforms are currently winning thousands of customers and millions of members, well beyond the pilot stage.
Hinge Health provides one of the cleanest examples. The company reported 2,929 clients in its latest quarter, up 24% year over year, while trailing-12-month calculated billings rose 52% to $862 million. Revenue grew even faster at 53%.
Omada offers another test because chronic-care programs depend heavily on employers and health plans agreeing to keep paying. Omada now reports more than 1.09 million members, more than 2,000 customers and a three-year average customer-retention rate above 90%. Its latest quarterly membership grew 45%.
The scale is also appearing inside physician workflows. OpenEvidence said earlier this year that its medical search product was being used daily by more than 40% of U.S. physicians and had crossed $100 million in revenue. Doximity says more than 85% of U.S. physicians belong to its network, while active prescribers using its workflow products grew more than 30% in its latest quarter.
These companies still have very different business models, but the pattern is hard to dismiss. A meaningful part of digital health has moved from “health system pilot” to recurring infrastructure that large populations actually use.
This chart, featured in our digital health market deck, shows how Hinge Health captured share in digital health
Is telehealth still growing, or did the pandemic boom end it?
Telehealth is still growing in healthcare usage today, although the standalone telehealth business model has become much less exciting.
FAIR Health's latest commercial-claims data shows telehealth rising from 5.01% of U.S. medical claim lines in the fourth quarter of 2025 to 5.51% in the first quarter of 2026, a relative increase of 10.1%. Usage increased in every U.S. region.
The percentage of commercially insured patients with at least one telehealth claim also rose from 17.3% to 18.4%.
The longer trajectory is more revealing. FAIR Health recorded telehealth at only 0.21% of medical claim lines in 2019. Current utilization is therefore roughly 26 times the pre-pandemic share, despite having fallen far below the exceptional 2020 peak.
At the company level, old-school telehealth is struggling. Teladoc's latest revenue fell 4%, and BetterHelp fell 12%. Teladoc's Integrated Care segment managed only 1% growth.
Telehealth itself has become normal healthcare infrastructure. Much of the growth now happens inside obesity care, psychiatry, chronic-care platforms, hospital virtual nursing and other services where video or messaging is simply part of the product.
If you want more recent data on this point, please see our latest digital health market report.
Is digital mental health still growing now?
Yes, digital mental health remains one of the strongest digital health categories today, but the winning model has changed a lot since the early teletherapy boom.
Mental health remains the top-funded clinical indication in Rock Health's latest U.S. dataset, extending a seven-year run in first place.
Patient behavior supports the investment story. FAIR Health found that 52.1% of commercially insured patients who used telehealth in the first quarter had a mental-health diagnosis. Mental health ranked first among telehealth diagnostic categories nationally, in every U.S. region and in every age group.
Capital is increasingly going to more integrated models. Talkiatry, which focuses on psychiatry, raised $210 million. Grow Therapy raised $150 million. Universal Health Services has now completed its $835 million acquisition of Talkspace, putting a national virtual mental-health platform inside one of the largest U.S. hospital and behavioral-health operators.
BetterHelp's 12% revenue decline shows how much the market has changed. Demand for digital mental healthcare remains large, but consumers paying cash for generic online therapy is no longer the only model that matters.
Insurance coverage, psychiatry, medication management and links between virtual and physical care are becoming much more important. Digital mental health is still growing, just through a different set of companies than many people would have expected a few years ago.
This chart, featured in our digital health market deck, shows annual funding in digital health startups
Is obesity care becoming one of digital health's biggest growth markets?
Yes, obesity and weight management have become one of the clearest growth areas in digital health now.
Rock Health ranks weight management and obesity as the second-most-funded clinical indication in the U.S. market, behind mental health. Among digital-health companies that raised money in mental health or weight management, 64% sold directly to consumers, compared with only 29% of funded digital-health companies overall.
Actual healthcare usage points in the same direction. FAIR Health found overweight and obesity among the leading telehealth diagnostic categories nationally, including a top-five position for adults aged 19 to 50.
Hims & Hers gives us the clearest commercial example. Its latest quarterly revenue grew 38% to $753 million, and subscribers reached nearly 2.9 million. The company's SEC filing says growth in its U.S. Hers business was driven mainly by weight loss and dermatology, with weight-loss offerings playing a major role in the current product mix.
The opportunity is also spreading around GLP-1 drugs themselves. Virtual providers can sell medical consultations, nutrition support, diagnostics, metabolic monitoring and long-term care alongside medication.
That makes obesity unusually attractive for digital health because the market combines huge consumer demand with a condition that often requires recurring care rather than a one-off transaction.
Is AI actually expanding the digital health market right now?
Yes, AI is already expanding digital health usage among both doctors and patients, and the adoption numbers have moved too far to dismiss as hype.
The American Medical Association's latest survey of 1,692 physicians found that 81% reported using AI professionally. In 2023, the figure was 38%. The average number of AI use cases reported by each physician also rose from 1.1 to 2.3.
Doctors are using AI for practical work. The AMA found 39% using it for research summaries, 30% for care-plan or progress-note generation, 28% for clinical documentation and 28% for chart summaries.
Consumers are moving quickly too. Rock Health's survey of 8,000 U.S. adults found that 32% had used an AI chatbot for health information, twice the 16% measured one year earlier. Among people already using AI for health, 64% did so at least weekly.
Doximity offers a more recent commercial check. Its latest results showed AI Search queries increasing more than 25% in a single quarter while workflow active prescribers grew more than 30% year over year.
Healthcare AI still has plenty of unanswered questions around accuracy, liability and workflow integration. Adoption itself is no longer one of them. Doctors and patients are already using these tools at meaningful scale.
This chart, featured in our digital health market deck, compares the main business model options for digital health SaaS platforms
Can digital health startups compete with ChatGPT for health questions?
Yes, digital health startups can still compete with ChatGPT, but a generic health chatbot has almost no moat anymore.
Rock Health's consumer survey found that nearly three-quarters of people who had used AI chatbots for health information had used ChatGPT. That represented 23% of all respondents. By comparison, only 5% had used a chatbot offered by a healthcare provider and 4% one offered by a payer.
Consumers essentially turned a general AI product into a health product before most healthcare companies could build their own interface.
That raises the bar for startups. Asking symptoms to an LLM, summarizing basic medical information or wrapping a general model in a health-themed interface can now be copied very quickly.
The companies with a stronger position control something outside the model. Tempus has clinical and molecular data plus diagnostic infrastructure. Doximity already owns physician distribution. Hinge and Omada have contracted populations and care programs. OpenEvidence has built a medical-information product with unusually deep physician usage.
AI is making digital health easier to build while making weak digital-health products easier to replace. Distribution, proprietary data, clinical workflow and outcomes are becoming more valuable than the chatbot itself.
If you want more recent data on this point, please see our latest digital health market report.
Are health wearables still growing, or has adoption topped out?
Health wearables are still becoming more valuable today, although the easy phase of adding millions of first-time device owners is slowing.
Rock Health's latest consumer survey found that 57% of U.S. adults owned at least one wearable or connected health device, while 46% specifically owned a wearable. Wearable ownership was only 13% in 2015.
First-time adoption has recently plateaued, according to the same research. Engagement tells a much stronger story: 83% of wearable owners use their device at least five days per week, and 59% wear it always or nearly always.
The latest capital-market activity suggests investors expect more value to come from that installed base. WHOOP raised $575 million earlier this year at a $10.1 billion valuation. Oura, valued at roughly $11 billion in its previous round, has confidentially filed for a U.S. IPO.
More recently, reports say Oura and some shareholders are considering raising as much as $3 billion in an IPO that could value the smart-ring company above $16 billion. The terms can still change, but a jump from roughly $11 billion to more than $16 billion would be a striking vote of confidence in the category.
The next wearable market looks less dependent on selling everybody their first tracker. Health interpretation, subscriptions, diagnostics and connections to actual healthcare services should matter much more from here.
This chart, featured in our digital health market deck, shows how revenue is split across customer segments in the digital health market
Are digital health companies finally making money?
Yes, several fast-growing digital health companies are profitable now, although we are still far from a market where profitability is normal.
Omada's latest quarter is a good example. Revenue grew 43%, gross margin climbed from 66% to 73%, and the company moved from a $5 million net loss to $5 million of net income.
Tempus also crossed an important line. Quarterly revenue grew 22%, adjusted EBITDA moved from negative $5.6 million to positive $8 million, and the company reported GAAP net income of $5.6 million, although unrealized investment gains helped that figure.
Doximity remains much more profitable than most digital-health companies, generating $75 million of adjusted EBITDA on $157 million of quarterly revenue, a margin close to 48%.
As seen above, Hinge Health is growing much faster than the market average. Its latest quarter also produced $40 million of GAAP operating income and almost $100 million of free cash flow.
Hims & Hers shows the opposite side. The company is growing quickly and produced $60 million of adjusted EBITDA, but it reported an $86 million GAAP net loss and negative free cash flow in the latest quarter.
So profitability is becoming real among category leaders, but we would be overstating the market if we called digital health broadly profitable. What has changed is that investors can now point to several scaled businesses where growth and positive economics exist at the same time.
Why are so many digital health companies getting bought right now?
Digital health M&A is running hot right now because large healthcare and software companies increasingly prefer buying proven products instead of building every capability themselves.
Rock Health counted 115 U.S. digital-health acquisitions in the first half of 2026, including 71 in the second quarter, its busiest quarter since 2021. That followed a 61% jump in digital-health M&A during 2025.
The activity has continued lately. Universal Health Services completed its roughly $835 million acquisition of Talkspace, combining a large physical behavioral-health network with virtual therapy and psychiatry. Francisco Partners agreed to acquire healthcare communications and payments company Weave for about $650 million. R1 agreed to acquire Humata Health to add AI-powered prior-authorization automation to its revenue-cycle platform.
There are smaller strategic combinations too. iRhythm agreed to buy VitalConnect, adding continuous multi-vital monitoring to its cardiac-monitoring business. DocGo agreed to acquire Hicuity Health, a virtual ICU, nursing and telemetry provider producing about $65 million of annual revenue.
These deals have a common shape. Buyers already have distribution and want another workflow, dataset or care capability. Digital-health companies with something useful can reach far more patients inside a larger platform.
Some acquisitions will still be rescue exits for companies that cannot raise another round. But the freshest deals show plenty of strategic buying as well.
| Recent digital health deal | Buyer | Value or target scale | What the buyer gets |
|---|---|---|---|
| Talkspace | Universal Health Services | ~$835M | Virtual behavioral health |
| Weave | Francisco Partners | ~$650M equity value | Patient engagement, payments and AI |
| Hicuity Health | DocGo | ~$65M target annual revenue | Virtual ICU, nursing and monitoring |
| Humata Health | R1 | Undisclosed | AI prior authorization |
This chart, featured in our digital health market deck, shows how remote patient monitoring platform technology has evolved over time
Are digital health IPOs really back?
Digital health IPOs are open again for strong companies, but the market still does not look easy enough to call the IPO drought over.
Hinge Health and Omada both went public in 2025, giving investors two large virtual-care businesses to judge on real revenue, margins and retention. Their latest results have held up well: Hinge is growing above 50%, while Omada is growing above 40% and has reached quarterly profitability.
The pipeline is getting more interesting now. Oura confidentially filed for a U.S. IPO earlier this year. Reports this week say the company could seek a valuation above $16 billion and raise as much as $3 billion, potentially making it one of the most important digital-health listings in years.
Oura would test something different from Hinge or Omada. Investors would be deciding whether a consumer wearable with subscriptions, health data and increasingly clinical ambitions deserves a healthcare-platform valuation.
Very few digital-health companies can meet that bar. The public market is rewarding scale and credible economics, while weaker companies continue to rely on private capital or acquisitions.
The IPO window has opened enough to matter. It has not opened wide enough to rescue the whole startup market.
If you want more recent data on this point, please see our latest digital health market report.
Is regulation helping the digital health market grow now?
Regulation is currently creating better routes for serious digital health companies to get paid, especially in chronic care.
The clearest new example is CMS's ACCESS model. The ten-year Medicare program has started with more than 150 accepted organizations and creates outcome-based payments for technology-enabled care in conditions including hypertension, diabetes, chronic musculoskeletal pain and depression.
The payment structure is important. Providers can earn money for delivering technology-supported care between traditional visits, but payment depends on clinical and patient-reported outcomes. That gives digital-health companies a clearer commercial route while forcing them to prove that their products actually work.
Telehealth policy has also become less precarious. Medicare's pandemic-era telehealth flexibilities have been extended through the end of 2027, giving virtual-care providers more visibility than repeated very short extensions did.
FDA guidance has meanwhile become clearer around lower-risk wellness products and clinical decision-support software. Companies can better understand when a product remains on the wellness side and when it moves into regulated medical-device territory.
Regulation will still slow some products down, particularly when companies make strong clinical claims. For the better digital-health businesses, though, clearer reimbursement and clearer rules are becoming an advantage rather than simply another obstacle.
In our digital health market deck, we identify pain points entrepreneurs should prioritize
So, is the digital health market growing now?
Yes. The digital health market is growing now, but the growth is concentrating around fewer and much stronger companies.
We found commercial growth across several independent measures. A group of six major public digital-health companies grew combined quarterly revenue by about 20%, and roughly 32% if we remove shrinking Teladoc. Telehealth usage recently rose again and remains around 26 times its pre-pandemic share of commercial medical claims. Physician AI adoption has moved from 38% in 2023 to 81% today. Consumer AI use for health questions doubled in one year. Mental health and obesity continue to pull in large amounts of capital and patient activity.
Capital markets support that conclusion, with an important warning attached. As seen above, U.S. digital-health funding rose from $6.4 billion to $7.4 billion in the first half while deal count stayed almost perfectly flat. Globally, the latest CB Insights data shows the fewest quarterly digital-health deals in more than a decade. Investors clearly want exposure to the market, but they are choosing far fewer companies to get it.
Recent M&A makes the same point from another angle. Talkspace is joining Universal Health Services. Weave is being acquired by Francisco Partners. R1 is buying Humata. DocGo is buying Hicuity. Larger platforms are pulling useful digital-health capabilities into broader healthcare businesses.
The strongest version of the answer is simple: digital healthcare is growing faster than the population of digital-health startups.
The companies benefiting most today tend to control something hard to reproduce: physician distribution, contracted patient populations, clinical data, reimbursement, a high-engagement consumer relationship or a workflow that sits directly inside healthcare operations. AI is accelerating this separation because basic software features have become easier to copy.
That is why the market can look strong and brutal at the same time. Patients are using more digital care. Doctors are using more AI. Revenue is growing at several leading platforms. Buyers are acquiring digital-health capabilities. Yet a generic point solution can still find the fundraising environment extremely difficult.
We would therefore call the claim mostly true, with high confidence. The digital health market is currently growing, but this is a consolidation cycle rather than another 2021-style startup boom.
OUR METHODOLOGY
This analysis tests whether the Digital Health Market is growing today by looking at the parts of the market where growth can actually be observed. Rather than relying on one market-size estimate, we compare capital formation, company revenue, customer and patient adoption, clinical usage, AI adoption, profitability, M&A, public-market activity and reimbursement.
We use a broad digital-health definition that includes virtual care, chronic-care platforms, clinical AI, healthcare workflow software, remote monitoring, wearables, digital mental health, consumer health platforms and parts of precision medicine. We treat AI drug discovery more cautiously because very large financings in that category can materially move digital-health funding totals without saying much about adoption elsewhere in the market.
We prioritized recent, observable evidence over forward-looking market forecasts. That includes venture funding and deal counts, reported quarterly financial results, healthcare claims, physician and consumer surveys, customer and membership figures, acquisitions, IPO activity and reimbursement developments.
Funding is never read in isolation. We compare capital raised with deal count, median deal size and mega-round concentration so that a handful of very large financings do not get mistaken for a broad reopening of the startup market.
We also separate market growth from startup growth. Digital healthcare activity can expand while investors fund fewer companies, and that distinction is central to the conclusion here. Revenue, usage and integration are moving forward even as venture capital becomes more concentrated.
Telehealth utilization is treated separately from the performance of standalone telehealth companies. FAIR Health claims data tells us whether patients are actually using telehealth, while Teladoc and BetterHelp show what is happening to particular business models inside that broader category.
For company performance, we compare several different digital-health models rather than relying on one standout company. Hims & Hers, Hinge Health, Omada Health, Tempus AI, Doximity and Teladoc Health provide a cross-section of consumer care, chronic care, healthcare AI, physician workflow and virtual-care businesses.
Our final judgment is based on the convergence of these different measures. When funding, revenue, healthcare utilization, AI adoption, customer scale, profitability and acquisitions point in the same direction, we treat that as stronger evidence than an isolated increase in valuation or venture activity.
Key sources used for this analysis include: Rock Health on H1 2026 U.S. digital-health funding and M&A, Rock Health's 2025 annual funding review, CB Insights on Q2 2026 global digital-health funding, FAIR Health on Q1 2026 telehealth utilization, the American Medical Association's 2026 Physician AI Survey, Rock Health's consumer AI-for-health survey, Hims & Hers financial results, Hinge Health's Q2 2026 results, Omada Health's Q2 2026 results, Tempus AI's Q2 2026 results, Doximity's fiscal Q1 2027 results, Teladoc Health's Q2 2026 results, WHOOP's Series G announcement, Universal Health Services on Talkspace, Francisco Partners on Weave, CMS on the ACCESS model, and FDA guidance on Clinical Decision Support Software.
This chart, featured in our digital health market deck, shows how revenue is distributed by region across Europe, Asia, North America, Africa, and South America in the digital health market
Related blog posts
- Is Nourish really worth $1.75B?
- Is Function Health really worth $2.5B?
- Who is furthest ahead in early dementia detection?
